MetaCap

SELLAS Life Sciences Group (SLS) vs Zai Lab (ZLAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed Zai Lab (ZLAB) over the past year, gaining 792.8% versus a gain of 5.0%. Over five years, SLS leads with a +94.0% price change compared with -72.7% for ZLAB. SELLAS Life Sciences Group is the larger company by market cap ($2.78 billion vs $2.63 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLS+792.81%ZLAB+5.04%
+1210%+567%-77%
Nov 21, 20251 yearNov 20, 2026
SLS+94.86%ZLAB-75.01%
+131%+14%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLS versus ZLAB key metrics
MetricSLSZLAB
Share price$13.66$21.03
Market cap$2.78B$2.63B
1-day change-8.08%-4.06%
YTD return+262.33%+19.22%
1-year return+792.81%+5.04%
5-year return+94.03%-72.67%
EPS (TTM)$-0.20$-1.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$460.16M
Revenue growth (YoY)—+15.33%
Net income (latest FY)$-26.86M$-175.54M
Gross margin—58.60%
Operating margin—-49.86%
Net margin—-38.15%
52-week high$24.89$29.02
52-week low$1.39$15.96
Distance from 52-week high-45.12%-27.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+137.92%+62.67%
Average volume9.64M991.34K
Shares outstanding203.86M124.84M
Employees131,784
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed ZLAB by 787.8 percentage points over the past year.

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Zai Lab

ZLAB stock →

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees

SLS vs ZLAB FAQ

Which is bigger, SELLAS Life Sciences Group or Zai Lab?

SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.78B compared with $2.63B for Zai Lab (ZLAB).

Which stock has performed better over the past year, SLS or ZLAB?

SLS returned +792.81% over the past 12 months, compared with +5.04% for ZLAB (price return, excluding dividends). Past performance does not predict future results.

Are SELLAS Life Sciences Group and Zai Lab in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons